WebFeb 28, 2024 · Cytek Biosciences, Inc. SALUGGIA, Italy, and FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex ... WebFeb 13, 2024 · SALUGGIA, Italy and FREMONT, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. ( CTKB) today …
Sale of Flow Cytometry and Imaging Business From DiaSorin to …
WebFeb 14, 2024 · Feb 14, 2024 (Heraldkeepers) -- The Clinical Flow Cytometry Market outlook looks extremely promising is a valuable source of insightful data for business strategists. It provides the industry ... WebThe FCI business unit, acquired by Luminex in October 2024, is based on both conventional flow cytometry and image-based flow cytometry instrumentation, which provide insights into all facets of cellular phenotypes and morphology. The FCI business unit includes dedicated commercial, operations, R&D, and supporting personnel. flying achievement bfa
Cytek Biosciences to acquire flow cytometry & imaging business …
WebFeb 28, 2024 · SALUGGIA (Italy), and FREMONT, California (USA), February 28, 2024 - DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly … WebApr 11, 2024 · By Application, the Bead-based flow cytometry segment has dominated the market, and it is growing at a CAGR of 79.30% over the forecast period 2024 to 2032. In 2024, North America dominated the market with the highest revenue share of 40.7%. WebFeb 28, 2024 · SALUGGIA, Italy, and FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & … flying achievement 9.2